Approval Granted for Additional Changes to Nblow's Dosage, Administration, and Precautions

Expected Organ Protection and Complication Prevention Effects Based on SGLT-2 Inhibitor Mechanism

Daewoong Pharmaceutical announced on April 9 that its new diabetes drug, Enblo Tablet (Inavogliflozin), has secured clinical evidence supporting its use in combination therapy with insulin preparations.


Daewoong Pharmaceutical 'Enblo'. Daewoong Pharmaceutical

Daewoong Pharmaceutical 'Enblo'. Daewoong Pharmaceutical

View original image

The Ministry of Food and Drug Safety approved an additional change to the "dosage and administration and precautions for use" of Enblo Tablet on March 19. This approval is based on multinational clinical trials conducted in Korea and Thailand. The study was completed in the first half of last year, after the clinical trial plan (IND) was submitted in July 2022.


According to the company, clinical results demonstrated both improved blood glucose control and safety when Enblo was administered together with insulin. As a result of the approval, standard precautionary statements to be checked when using insulin in combination will be reflected on the product label.


Diabetes is a progressive disease in which the pancreas’ ability to secrete insulin declines over time. At certain stages, proper blood glucose management requires a combination of oral agents and insulin therapy. Enblo is an SGLT-2 inhibitor that works by directly excreting glucose through the urine. When used in combination with insulin, it can supplement the glucose-lowering effect. The company explained that securing this clinical evidence provides institutional and medical grounds to offer treatment options tailored to patient conditions in clinical practice.


The efficacy of Enblo is based on a chain of metabolic improvements that starts with blocking glucose reabsorption in the kidneys—a mechanism common to SGLT-2 inhibitors. Blood sugar control and metabolic normalization through urinary glucose excretion are known to begin by reducing pancreatic burden, subsequently improving fat metabolism and suppressing cardiovascular and renal complications in a stepwise manner.


According to the company, clinical results for Enblo showed stabilization of fasting C-peptide levels, an approximately 30% improvement in HOMA-IR, an insulin resistance marker, compared to dapagliflozin, and a reduction in the prevalence of fatty liver disease from 48% to 16%. SGLT-2 inhibitors are known to help prevent damage by relieving excessive pressure within the glomerulus through the excretion of glucose and sodium in the urine, thereby regulating blood flow into the kidneys. The company expects that, based on this mechanism, Enblo will help protect major organ functions, such as the pancreas, heart, and kidneys, and reduce the risk of complications.



The latest domestic and international guidelines for diabetes and cardiovascular care define SGLT-2 inhibitors as essential agents for the prevention of complications. With clinical evidence now established for combination therapy with insulin, Enblo is considered to be more closely aligned with the latest treatment directions set forth by global guidelines.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing